Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease
NCT ID: NCT00928629
Last Updated: 2009-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1000 participants
INTERVENTIONAL
2009-06-30
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention
NCT00689377
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
NCT05308030
Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients
NCT04269863
Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs
NCT00970918
Novel Blood Biomarker for Peripheral Arterial Disease
NCT05596136
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Subjects
ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
Ankle-brachial index (ABI) Screening Test
Patients will undergo an ABI measurement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ankle-brachial index (ABI) Screening Test
Patients will undergo an ABI measurement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least two other risk factors for CVD: cigarette smoking, diabetes mellitus, hypertension, low HDL or high LDL cholesterol, strong family history of coronary heart disease, elevated waist circumference, Aboriginal and/or Torres Strait Islander.
* Willingness to participate in study and sufficient command of the English language to read and complete study questionnaire.
Exclusion Criteria
* No lipid data collected in the last 12 months
* Serious or unstable medical or psychological conditions that, in the opinion of the Investigator, would compromise safety or successful participation in the study.
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pretium Pty Ltd
UNKNOWN
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon Fisher
Role: STUDY_DIRECTOR
AstraZeneca
Amelia Siu
Role: STUDY_DIRECTOR
AstraZeneca
David Sullivan
Role: PRINCIPAL_INVESTIGATOR
Central Clinical School, The University of Sydney, Sydney, Australia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Edgecliff, New South Wales, Australia
Research Site
Hinchinbrook, New South Wales, Australia
Research Site
Kingsford, New South Wales, Australia
Research Site
Kingswood, New South Wales, Australia
Research Site
Liverpool, New South Wales, Australia
Research Site
Mosman, New South Wales, Australia
Research Site
Neutral Bay, New South Wales, Australia
Research Site
Sydney, New South Wales, Australia
Research Site
Aspley, Queensland, Australia
Research Site
Morayfield, Queensland, Australia
Research Site
Parkwood, Queensland, Australia
Research Site
Beulah Park, South Australia, Australia
Research Site
Glenelg East, South Australia, Australia
Research Site
Surrey Downs, South Australia, Australia
Research Site
Bridgewater, Tasmania, Australia
Research Site
Kingston, Tasmania, Australia
Research Site
Sandy Bay, Tasmania, Australia
Research Site
Brighton, Victoria, Australia
Research Site
Lalor, Victoria, Australia
Research Site
Preston, Victoria, Australia
Research Site
Booragoon, Western Australia, Australia
Research Site
East Victoria Park, Western Australia, Australia
Research Site
Woodvale, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D3560L00089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.